Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Roche
Roche
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
OBR Oncology
Fri, 10/20/23 - 10:05 am
ESMO
non-small cell lung cancer
Roche
Alecensa
AstraZeneca
Tagrisso
JNJ
Rybrevant
Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific
Fierce Biotech
Thu, 10/19/23 - 11:36 am
Roche
diabetic retinopathy
solid tumors
bispecific antibodies
Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales
Reuters
Thu, 10/19/23 - 10:03 am
Roche
earnings
Vabysmo
Roche pays $50M upfront to Monte Rosa in molecular glue deal
Fierce Biotech
Tue, 10/17/23 - 09:46 pm
Roche
molecular glue
Monte Rosa
QuEEN
protein degradation
Roche builds gene therapy portfolio with SpliceBio deal
Pharmaphorum
Tue, 10/17/23 - 11:00 am
Roche
Spark Therapeutics
SpliceBio
gene therapy
inherited retinal disease
Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion
Fierce Pharma
Wed, 10/11/23 - 10:13 am
Roche
retinal vein occlusion
Vabysmo
Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study
Fierce Pharma
Wed, 10/11/23 - 10:07 am
Roche
Ocrevus
MS
multiple sclerosis
clinical trials
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
BioSpace
Wed, 10/4/23 - 09:41 am
Roche
Genentech
clinical trials
Evrysdi
SMA
Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra
Fierce Pharma
Mon, 10/2/23 - 11:48 am
Biogen
Roche
Actemra
autoimmune disease
biosimilars
In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset
Fierce Pharma
Fri, 09/29/23 - 12:13 pm
AbbVie
Roche
Venclexta
Multiple Myeloma
Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs
Fierce Biotech
Wed, 09/27/23 - 10:14 am
Roche
Ionis Pharmaceuticals
RNA
Alzheimer's disease
Huntington's disease
Roche condemns 'act of counterfeiting' as authorities in Pakistan crack down on unapproved Avastin use
Fierce Pharma
Mon, 09/25/23 - 07:42 pm
Roche
Avastin
Pakistan
drug counterfeiting
Roche scores—again—in hemophilia drug patent case against Takeda
Fierce Pharma
Thu, 09/21/23 - 11:47 am
Roche
Takeda
patents
legal
Genentech
Baxalta
hemophilia
Roche hits FDA delay with subcutaneous version of Tecentriq amid manufacturing process changes
Fierce Pharma
Thu, 09/7/23 - 10:53 pm
Roche
FDA
Tecentriq
Halozyme
Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win
BioSpace
Thu, 09/7/23 - 10:49 pm
Alnylam
Roche
PAH
zilebesiran
clinical trials
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Merck’s Keytruda to top drug sales in 2028, as Roche takes pharma crown
Medical Marketing and Media
Fri, 08/25/23 - 09:55 am
Merck
Keytruda
Roche
branding
Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors
BioSpace
Thu, 08/24/23 - 11:50 am
Roche
Genentech
divarasib
KRAS inhibitors
solid tumors
clinical trials
Roche, Horizon lead way for pharma reputation among rare disease patient groups
Medical Marketing and Media
Wed, 08/23/23 - 05:49 pm
Roche
Horizon Pharma
reputation
rare disease
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »